IgG4 Related Disease
13
5
8
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.7%
1 terminated out of 13 trials
66.7%
-19.8% vs benchmark
15%
2 trials in Phase 3/4
150%
3 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
Zanubrutinib in Patients With IgG4-Related Disease
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients